[Chemotherapy of advanced breast cancer--actual results ]

The preliminary results of a prospective controlled study for a first-line-therapy in women with hormone-resistant advanced breast cancer are reported. Two therapy-regimens were compared: 1) cyclophosphamide, methotrexate and ftorafur (CMFt) and 2) cyclophosphamide and ftorafur (CFt). The overall objective response rate for both treatment groups was 30%, the duration of remission was 10 months in the CMFt-regimen and 5 months in the CFt-regimen. 21 patients were subsequently treated with the non-cross-resistant combination adriamycin and vincristine (AV) after either relapse or failure of the firstline modalities. 33% of the AV-group obtained further palliation with a median duration of 7 months, objective response was not seen.